吐故纳新 糖尿病治疗的新靶点参考.pptVIP

* Mean (SD) weight change per category: Liraglutide 1.8 mg Placebo Weight gain: 2.03 (0.01) 2.44 (0.14) Loss 0-3%: -1.28 (0.04) -1.12 (0.06) Loss 3-5%: -3.54 (0.07) -3.35 (0.11) Loss 5%: -6.84 (0.15) -6.52 (0.37) * * Liraglutide reduces both FPG and PPG References Studies NN2211-1436, -1572, -1573, and-1697 presented as Marre et al. Diabetes 2008; 57 (Suppl. 1): A4 Nauck et al. Diabetes 2008; 57 (Suppl. 1): A150 Garber et al. Diabetes 2008; 57 (Suppl. 1): LB3 Russell-Jones et al. Diabetes 2008; 57 (Suppl. 1): A159 Study NN2211-1574 presented as poster 898 by Zinman at EASD 2008 * * * 利拉鲁肽 reduces visceral body fat 利拉鲁肽, a once-daily human GLP-1 analogue: Reduced body weight with concomitant improvement in HbA1c Had a more pronounced effect on fat tissue than on lean tissue Reduced body fat percentage with marked reductions in visceral adipose tissue and subcutaneous adipose tissue Reduced hepatic steatosis Reference Jendle et al. Diabetes 2008; 57 (Suppl. 1): A32 * * * Clinicians often face a dilemma in diabetes therapy: a choice between achieving recommended glycemic targets and avoiding therapy?limiting hypoglycemia. With some diabetes treatments, the risk of hypoglycemia generally increases as A1C levels approach the target range of 6.5– 7.0%. Liraglutide, a once-daily human GLP-1 analog that stimulates insulin secretion in a glucose-dependent manner, was tested alone or in combination with oral antidiabetic drugs (OAD) in six phase 3 randomized controlled trials in 3967 subjects vs. active comparators. A meta-analysis of these trials examined rates of hypoglycemic events as a function of A1C values at Week 26 using individual patient data. All analyses were intent-to-treat with last observation carried forward. Lower A1C values were associated with increased rates of hypoglycemia with glimepiride while rates of hypoglycemia with liraglutide remained very low (